Xiao Liu

· Assistant Professor

Arizona State University · Information Systems

Active 1997–2026

h-index71

Citations17.8k

Papers316107 last 5y

Funding—

Academic metrics are sourced from OpenAlex and public funding records; values may differ from Google Scholar.

Faculty page Website

See your match with Xiao Liu — sign in to PhdFit.Sign in

About

Xiao Liu is an assistant professor in the Department of Information Systems at Arizona State University. She holds a Ph.D. in Management Information Systems from the Eller College of Management at the University of Arizona. Her research interests include data science and predictive analytics in healthcare, education, and fintech. Her work has been published in several academic journals and peer-reviewed conferences, such as MIS Quarterly, Journal of Management Information Systems, Journal of Medical Internet Research, Journal of the American Medical Informatics Association, and the International Conference in Information Systems. Her research activity includes a grant from the National Institutes of Health to leverage YouTube video analytics for patient education on health management, where she serves as the ASU Site Principal Investigator. She also teaches courses related to machine learning, analytics of unstructured data, and data mining at Arizona State University.

Research topics

Psychiatry
Medicine
Clinical psychology
Psychology
Internal medicine
Demography
Environmental health
Virology
Bioinformatics
Immunology

Selected publications

Psychometric properties of the Chinese version of Nightmare Distress Questionnaire in adolescents with psychiatric disorders.
Dreaming · 2025-01-09
articleSenior author
Publisher DOI
Abstract P4-12-04: Real-world effectiveness of palbociclib plus an aromatase inhibitor in HR+/HER2- MBC patients living in disadvantaged neighborhoods
Clinical Cancer Research · 2025-06-13
article
Abstract Background: Palbociclib (PAL) in combination with endocrine therapy (ET) has been approved for hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced/metastatic breast cancer (MBC) since February 2025. Despite extensive real-world data in a variety of populations, little is known about the use and effectiveness of PAL combination in MBC patients living in disadvantaged neighborhoods. The current study aimed to compare overall survival (OS) and r…
Publisher DOI
Abstract PS2-03: Comparative overall survival of CDK4/6is plus an aromatase inhibitor (AI) in HR+/HER2- MBC in the US real-world setting
Clinical Cancer Research · 2025-06-13
article
Abstract Background: Palbociclib (PAL), the first CDK4/6i, in combination with endocrine therapy (ET) was approved for HR+/HER2- advanced/metastatic breast cancer (MBC) in 2015. Two additional CDK4/6is, Ribociclib (RIB) and Abemaciclib (ABE), were approved in 2017. CDK4/6i combination therapy has become standard of care for 1st line HR+/HER2- MBC. Randomized clinical trials (RCT) demonstrated that the 3 CDK4/6is plus ET vs ET plus placebo all significantly prolonged patients’ progression free su…
Publisher DOI

Frequent coauthors

Cun-Xian Jia
Shandong University
167 shared
Zhenzhen Liu
Sun Yat-sen University
112 shared
Shihua Sun
52 shared
Yanyun Yang
Florida State University
51 shared
Xia Hu
49 shared
Jiyu Zhang
49 shared
Hui-Min Qiu
Shandong Mental Health Center
49 shared
Bao-Peng Liu
Shandong University
34 shared

Education

Ph.D., Management Information Systems
The University of Arizona

Similar researchers at Arizona State University

Resume-aware match score
Save to shortlist
AI-drafted outreach

See your match with Xiao Liu

PhdFit ranks faculty by your research interests, methods, and publications — grounded in their actual work, not templates.

Free to start
No credit card
30-second signup